Hengrui Pharma Shares Surge on Positive ASCO Presentation for Liver Cancer Treatment Combo

Hengrui Pharma Conducts Share Buyback on June 4th

Jiangsu Hengrui files HKEX next-day return disclosing share buyback at RMB 47.2 per share

Major Tech and Pharma Stocks Decline in Hong Kong Market

Hengrui Pharma Reports Cumulative Share Buyback of 12.06 Million A-Shares by End of May

HENGRUI PHARMA Reports 2025 Revenue of 31.63 Billion Yuan, Up 13.02% Year-on-Year

DIARY-China corporate earnings week ahead

HENGRUI PHARMA's Novel Drug SHR4640 Tablets Receive Marketing Authorization

Jiangsu Hengrui Pharmaceuticals - Received Nmpa Notice Approving Class 1 Innovative Drug Ruzinurad Tablets (Shr4640 Tablets) for Marketing

HENGRUI PHARMA's Subsidiary Receives Clinical Trial Approval for SHR-1819 Injection

Jiangsu Hengrui Pharmaceuticals Says Shr4640 Approved by China's Medical Products Administration for Treating Patients With Gout and Hyperuricemia

Pharmaceutical Sector Shows Resilience at Low Levels, Huabao Pharma ETF (562050) Rises Against Market Trend in Afternoon Session! Leading Stock Hengrui Pharma Surges 4%, Traditional Chinese Medicine Leaders All in the Green

HENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial

Hengrui Pharma Gets China Regulatory Nod for Catabolic Drug

HENGRUI PHARMA's ω-3 Triglyceride (2%) MCT/LCT Fat Emulsion/Amino Acids (16)/Glucose (30%) Receives Drug Registration Approval

Schroders PLC Increases Stake in Hengrui Pharma by 663,000 Shares

Hengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk

HENGRUI PHARMA's Subsidiary Gains Approval for Clinical Trials of SHR-3079 Injection

Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion

Dow Jones Top Company Headlines at 9 AM ET: EBay Rejects GameStop's $56 Billion Takeover Proposal | Under ...